Skip to main content
DeutschDE
European Commission logo print header

Establishment of embryonic stem cells and gene targeting technology in rats for investigation of the genetic basis of cardiovascular disease

Ziel

The objective of this programme is to facilitate the use of homologous recombination in the rat. The long-term aim is achieve a better understanding of the role of specific genes in normal and abnormal blood pressure regulation.

The rat is the species of choice for many areas of biomedical research, including hypertension and neurobiology, however existing techniques of germline modification in this species are limited. Although it is technically possible to produce transgenic rats by DNA microinjection, the ability to introduce precise genetic alterations is severely limited by the lack of suitable embryonic stem cells. To date all attempts to isolate such cell lines have not resulted in successful germline transmission. Further efforts and new approaches are therefore required to obtain suitable cell lines. Our aim is to develop a generic method of ES cell derivation through a selection-based approach in order to extend stem cell technology into this species. If the selection methodology is successful this would eventually permit germline manipulation of existing phenotypically selected models of hypertension such as the Spontaneously Hypertensive Rat (SHR), and would enable the future developments to other rat strains of interest to biomedical researchers studying of human disease.

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

CSC - Cost-sharing contracts

Koordinator

University of Edinburgh
EU-Beitrag
Keine Daten
Adresse
West Main Road
EH9 3JQ EDINBURGH
Vereinigtes Königreich

Auf der Karte ansehen
Gesamtkosten
Keine Daten

Beteiligte (1)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 3 Juli 2002

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/BMH4961516/de

European Union, 2024